Patrick Baeuerle

Executive Partner at MPM Capital Inc

Patrick Baeuerle

Patrick Baeuerle

Executive Partner at MPM Capital Inc

Overview
Career Highlights

Cullinan Oncology LLC
iOmx Therapeutics AG
TCR2 Therapeutics, Inc.

RelSci Relationships

2430

Number of Boards

9

Birthday

1958

Age

63

Relationships
RelSci Relationships are individuals Patrick Baeuerle likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at MPM Capital Inc

Relationship likelihood: Strong

Co-Founder at MPM Capital Inc

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Founder at F2 Capital Ventures LLP

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Director, President & Chief Executive Officer at TCR2 Therapeutics, Inc.

Relationship likelihood: Strong

Chief Financial Officer & Chief Operating Officer at MPM Capital Inc

Relationship likelihood: Strong

Executive Partner at MPM Capital Inc

Relationship likelihood: Strong

Paths to Patrick Baeuerle
Potential Connections via
Relationship Science
You
Patrick Baeuerle
Executive Partner at MPM Capital Inc
Education
Doctorate Degree

Ludwig-Maximilians-Universität München is a premier academic and research institutions.

Doctorate Degree

The Max Planck Institute of Molecular Genetics Berlin focuses on research in the fields of molecular genetics.

Memberships
Career History
Co-Founder
2016 - Current

Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Chief Scientific Officer-Biologics
2016 - Current

Cullinan Management, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.

Co-Founder
2016 - Current

iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.

Boards & Committees
Member, Board of Directors
Prior

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Member, Board of Directors
Prior

Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA.

Investments
Details Hidden

Werewolf Therapeutics, Inc. engages in the development of treatment for cancer. It offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin and Luke B. Evnin and is headquartered in Cambridge, MA.

Details Hidden

iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.

Details Hidden

Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Patrick Baeuerle. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Patrick Baeuerle's profile does not indicate a business or promotional relationship of any kind between RelSci and Patrick Baeuerle.